Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin and Bendamustine in Relapsed/Refractory HL or ALCL
NCT01657331Phase 2Completed
- Sponsor
- Columbia University
- Start
- Jul 2012
- Primary completion
- Jun 2018
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of brentuximab vedotin, bendamustine in Hodgkin lymphoma (HL), anaplastic large cell lymphoma (ALCL), sponsored by Columbia University. Started Jul 2012; status: completed.
02
Drugs
brentuximab vedotinbendamustine
03
Conditions
Hodgkin lymphoma (HL)anaplastic large cell lymphoma (ALCL)
Beyond the preview
Go deeper on NCT01657331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01657331.